Cassandra Pardini, PharmD

Suppressed drug metabolism was identified in patients with various inflammatory conditions.

Although NASH is a common cause of chronic liver disease, there is limited evidence surrounding its management.

The study authors obtained randomized clinical trials comparing oseltamivir, peramivir, zanamivir, and baloxavir with other active agents or placebo.

The study authors utilized the National Social Life, Health, and Aging Project leave-behind questionnaire to obtain data on a total of 6017 adults over 65 years of age.

While DAAs have improved the treatment of chronic HCV infection by eliciting higher rates of sustained virologic response, they also interact with a number of agents that could potentially limit their effectiveness.

The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.

Ticagrelor and prasugrel, the newer generation of P2Y12-inhibiting antiplatelet agents, were found to be associated with fewer gastrointestinal bleeding events the first year after percutaneous coronary intervention compared with clopidogrel.

A recently published report describes the case of a 61-year-old male patient who experienced antacid-induced hypercalcemia and highlights the importance of performing thorough medication reconciliation.

There is a lack of evidence supporting the use of dietary supplements for the prevention or treatment of COVID-19, despite what recent news or social media platforms have asserted,

Study data showed digestive symptoms became more pronounced as the severity of the disease increased.

Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.

For older patients with type 2 diabetes mellitus, higher levels of seroprotection against the hepatitis B virus were obtained following the receipt of the 2-dose vaccine vs the 3-dose vaccine.